Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 8293-8307

  Jiang, Chunguo ^a   Huang, Hui ^a   Liu, Jia ^a   Wang, Yanxun ^a   Lu, Zhiwei ^b   Xu, Zuojun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

Connective tissue growth factor; Fasudil; Plasminogen activator inhibitor 1; Pulmonary fibrosis; Transforming growth factor 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; CONNECTIVE TISSUE GROWTH FACTOR; FASUDIL; HYDROXYPROLINE; MYOSIN; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; CYTOKINE; MYOSIN LIGHT CHAIN KINASE; MYPT1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASCHCROFT SCORE; CONTROLLED STUDY; DRUG DOSE COMPARISON; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG HOMOGENATE; LUNG LAVAGE; LYMPHOCYTE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; LUNG; MACROPHAGE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PULMONARY FIBROSIS;

MUS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BLEOMYCIN; CYTOKINES; DRUG EVALUATION, PRECLINICAL; LUNG; LYMPHOCYTES; MACROPHAGES; MALE; MICE, INBRED C57BL; MYOSIN-LIGHT-CHAIN KINASE; NEUTROPHIL INFILTRATION; PULMONARY FIBROSIS; RHO-ASSOCIATED KINASES;

EID: 84864371060     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13078293     Document Type: Article

References (46)

1. Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A.; et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788-824.
2. Gross, T.J.; Hunninghake, G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001, 345, 517-525.
3. Raghu, G.; Weycker, D.; Edelsberg, J.; Bradford, W.Z.; Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006, 174, 810-816.
4. Shimokawa, H.; Takeshita, A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc. Biol. 2005, 25, 1767-1775.
5. Niggli, V. Rho-kinase in human neutrophils: A role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett. 1999, 445, 69-72.
6. Shimizu, Y.; Dobashi, K.; Iizuka, K.; Horie, T.; Suzuki, K.; Tukagoshi, H.; Nakazawa, T.; Nakazato, Y.; Mori, M. Contribution of small GTPase Rho and its target protein ROCK in a murine model of lung fibrosis. Am. J. Respir. Crit. Care Med. 2001, 163, 210-217.
7. Bonniaud, P.; Margetts, P.J.; Ask, K.; Flanders, K.; Gauldie, J.; Kolb, M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J. Immunol. 2005, 175, 5390-5395.
8. Kothapalli, D.; Frazier, K.S.; Welply, A.; Segarini, P.R.; Grotendorst, G.R. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ. 1997, 8, 61-68.
9. Watts, K.L.; Spiteri, M.A. Connective tissue growth factor expression and induced by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287, L1323-L1332.
10. Watts, K.L.; Cottrell, E.; Hoban, P.R.; Spiteri, M.A. RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir. Res. 2006, 7, doi:10.1186/1465-9921-7-88.
11. Hemnes, A.R.; Zaiman, A.; Champion, H.C. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 294, L24-L33.
12. Mouratis, M.A.; Aidinis, V. Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 2011, 17, 355-361.
13. Bergeron, A.; Soler, P.; Kambouchner, M.; Loiseau, P.; Milleron, B.; Valeyre, D.; Hance, A.J.; Tazi, A. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and il-10. Eur. Respir. J. 2003, 22, 69-76.
14. Kenyon, N.J.; Ward, R.W.; McGrew, G.; Last, J.A. TGF-β1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax 2003, 8, 772-777.
15. Golan-Gerstl, R.; Wallach-Dayan, S.B.; Amir, G.; Breuer, R. Epithelial cell apoptosis by fas ligand-positive myofibroblasts in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2007, 36, 270-275.
16. Senoo, T.; Hattori, N.; Tanimoto, T.; Furonaka, M.; Ishikawa, N.; Fujitaka, K.; Haruta, Y.; Murai, H.; Yokoyama, A.; Kohno, N. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010, 65, 334-340.
17. Goldstein, R.H.; Fine, A. Potential therapeutic initiatives for fibrogenic lung diseases. Chest 1995, 108, 848-855.
18. Moore, B.B.; Hogaboam, C.M. Murine models of pulmonary fibrosis. Am. J. Physiol. 2008, 294, L152-L160.
19. Singh, R.; Wang, B.; Shirvaikar, A.; Khan, S.; Kamat, S.; Schelling, J.R.; Konieczkowski, M.; Sedor, J.R. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J. Clin. Invest. 1999, 103, 1561-1570.
20. Montaner, S.; Perona, R.; Saniger, L.; Lacal, J.C. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J. Biol. Chem. 1998, 273, 12779-12785.
21. Higashi, M.; Shimokawa, H.; Hattori, T.; Hiroki, J.; Mukai, Y.; Morikawa, K.; Ichiki, T.; Takahashi, S.; Takeshita, A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ. Res. 2003, 93, 767-775.
22. Radeff, J.M.; Nagy, Z.; Stern, P.H. Rho and Rho kinase are involved in parathyroid hormone stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. J. Bone Miner. Res. 2004, 19, 1882-1891.
23. Takemoto, M.; Sun, J.; Hiroki, J.; Shimokawa, H.; Liao, J.K. Rho-kinasemediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106, 57-62.
24. Funakoshi, Y.; Ichiki, T.; Shimokawa, H.; Egashira, K.; Takeda, K.; Kaibuchi, K.; Takeya, M.; Yoshimura, T.; Takeshita, A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38, 100-104.
25. Hattori, T.; Shimokawa, H.; Higashi, M.; Hiroki, J.; Mukai, Y.; Kaibuchi, K.; Takeshita, A. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ. Res. 2004, 94, 46-52.
26. Steinberg, K.P.; Hudson, L.D.; Goodman, R.B.; Hough, C.L.; Lanken, P.N.; Hyzy, R.; Thompson, B.T.; Ancukiewicz, M. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 2006, 354, 1671-1684.
27. Khalil, N.; O'Connor, R.N.; Flanders, K.C.; Unruh, H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: An immunohistochemical study. Am. J. Respir. Cell Mol. Biol. 1996, 14, 131-138.
28. Border, W.A.; Noble, N.A. Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 1994, 331, 1286-1292.
29. Duncan, M.R.; Frazier, K.S.; Abramson, S.; Williams, S.; Klapper, H.; Huang, X.; Grotendorst, G.R. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP. FASEB. J. 1999, 13, 1774-1786.
30. Giri, S.N.; Hyde, D.M.; Hollinger, M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993, 48, 959-966.
31. Sime, P.J.; Xing, Z.; Graham, F.L.; Csaky, K.G.; Gauldie, J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 1997, 100, 768-776.
32. Lasky, J.A.; Ortiz, L.A.; Tonthat, B.; Hoyle, G.W.; Corti, M.; Athas, G.; Lungarella, G.; Brody, A.; Friedman, M. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 1998, 275, L365-L371.
33. Liu, M.; Gu, M.; Wu, Y.; Zhu, P.; Zhang, W.; Yin, C.; Zhang, W.J. Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats. J. Surg. Res. 2009, 157, e117-e127.
34. Wu, G.; Tu, Y.; Jia, R. The influence of fasudil on the epithelial-mesenchymal transdifferentiation of renal tubular epithelial cells from diabetic rats. Biomed. Pharmacother. 2010, 64, 124-129.
35. Lee, C.G.; Cho, S.; Homer, R.J.; Elias, J.A. Genetic control of transforming growth factor-beta1-induced emphysema and fibrosis in the murine lung. Proc. Am. Thorac. Soc. 2006, 3, 476-477.
36. Cutroneo, K.R.; White, S.L.; Phan, S.H.; Ehrlich, H.P. Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J. Cell Physiol. 2007, 211, 585-589.
37. Idell, S.; James, K.K.; Levin, E.G. Schwartz, B.S.; Manchanda, N.; Maunder, R.J.; Martin, T.R.; McLarty, J.; Fair, D.S. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J. Clin. Invest. 1989, 84, 695-705.
38. Bertozzi, P.; Astedt, B.; Zenzius, L.; Lynch, K.; LeMaire, F.; Zapol, W.; Chapman, H.A., Jr. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N. Engl. J. Med. 1990, 322, 890-897.
39. Chapman, H.A.; Allen, C.L.; Stone, O.L. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am. Rev. Respir. Dis. 1986, 133, 437-443.
40. Eitzman, D.T.; McCoy, R.D.; Zheng, X.; Fay, W.P.; Shen, T.; Ginsburg, D.; Simon, R.H. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 1996, 97, 232-237.
41. Nishikimi, T.; Koshikawa, S.; Ishikawa, Y.; Akimoto, K.; Inaba, C.; Ishimura, K.; Ono, H.; Matsuoka, H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J. Hypertens. 2007, 25, 1053-1063.
42. Ishimaru, K.; Ueno, H.; Kagitani, S.; Takabayashi, D.; Takata, M.; Inoue, H. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J. Cardiovasc. Pharmacol. 2007, 50, 187-194.
43. Vicari, R.M.; Chaitman, B.; Keefe, D.; Smith, W.B.; Chrysant, S.G.; Tonkon, M.J.; Bittar, N.; Weiss, R.J.; Morales-Ballejo, H.; Thadani, U. Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 2005, 46, 1803-1811.
44. Ashcroft, T.; Simpson, J.M.; Timbrell, V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 1988, 41, 467-470.
45. Nie, L.; Xiang, R.; Zhou, W.; Lu, B.; Cheng, D.; Gao, J. Attenuation of acute lung inflammation induced by cigarette smoke in CXCR3 knockout mice. Respir. Res. 2008, 9, 82.
46. Moore, B.B.; Paine, R., 3rd.; Christensen, P.J.; Moore, T.A.; Sitterding, S.; Ngan, R.; Wilke, C.A.; Kuziel, W.A.; Toews, G.B. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 2001, 167, 4368-4377.